Astrazeneca Pharma yesterday evening announced that it has received import and market permission in Form CT-20 (Marketing Authorization) from the Drugs Controller General of India for Benralizumab 30mg/mL solution for injection.

Benralizumab is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.

The receipt of this permission paves way for the launch of Benralizumab in India, subject to the receipt of related statutory approvals and licenses.

The stock price surged 2% to Rs.4429.60 and it has come off the intraday high and is now trading at Rs.443 levels.